Day: January 19, 2021

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Carla Poulson has joined the company as Chief Human Resources Officer.“Carla has substantial experience in organizational and talent development that will be instrumental to Mersana as we scale the Company to accommodate a maturing and expanding pipeline. More importantly, Carla shares Mersana’s core values and commitment to an organization focused on scientific rigor and patient needs. I am confident that Carla will have a great impact,” said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. “On behalf of our...

Initiation of the Phase 2b FREEDOM trial represents the next step in development of CLBS16 as a potential breakthrough treatment for the millions of sufferers of CMD in the U.S., most of whom are womenPatient enrollment underway at The Christ Hospital Health Network in Cincinnati (OH) and Mayo Clinic in Rochester (MN) with additional sites across the United States targeted to open soonStrong investigator and subject interest driven by the positive results of the Phase 2a ESCaPE-CMD trial reported in spring of 2020BASKING RIDGE, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announced that it has treated the first patient in its Phase 2b FREEDOM...

NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, today announced that Founder and CEO Eric Weisblum will participate in the “Investing in Psychedelics Series: Building Value Through IP” virtual conference hosted by The Canadian Securities Exchange (CSE), CFN Media Group (OTCQB: CNFN) and Zuber Lawler on Wednesday, January 20, 2021. The live panel discussion is scheduled to begin at 1 PM EST. and will be followed by a Q&A session.For more information and to register for this free conference, please visit the conference website at  https://promo.cfnmedia.com or contact...

TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) — WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally licensed producer and distributor of medical-grade cannabis, is pleased to announce it is kicking off 2021 with the development of new extract products featuring live resin and solventless hash, and rosin concentrates. The Company’s newest Cannabis 2.0 extract products are expected to debut during the second quarter of 2021, under WeedMD’s Color Cannabis and Saturday Cannabis adult-use brands.“WeedMD’s genetic library boasts unique strains, with flavour and aroma profiles widely recognized throughout the industry and we are thrilled to announce we are now expanding into high-value, terpene-rich hash, live resin and rosin products,” said George Scorsis, Executive Chairman and Interim CEO, WeedMD. “We...

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced its corporate partners, Alphamab Oncology and 3D Medicines, received notification that the New Drug Application (NDA) for envafolimab was granted priority review by the Center for Drug Evaluation of the National Medical Products Administration (NMPA) in the indication of MSI-H/dMMR cancer.“We congratulate our partners on the acceptance of the initial regulatory submission for envafolimab in China for priority review, which marks another...

VANCOUVER, British Columbia, Jan. 19, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board (“DSMB”) has completed its latest review of the Phase 2b part of the Company’s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the Company to continue on with the Phase 3 part of the study.The DSMB is a committee of clinical research experts, including physicians, statisticians, and patient advocates, who are monitoring the progress of the Company’s clinical trial, and are reviewing safety and effectiveness data while the trial is ongoing.“While we await final data from the Phase 2b part...

Houston, TX, Jan. 19, 2021 (GLOBE NEWSWIRE) — EDPR Renewables North America LLC (EDPR NA) announces the acquisition of a majority interest in C2 Omega LLC, the distributed solar platform of C2 Energy Capital LLC (“C2”). The new company, EDPR NA Distributed Generation LLC (EDPR NA DG), will be the exclusive provider of small-scale downstream generation and energy efficiency services in the United States for EDPR NA.With approximately 200 projects across 16 states, this acquisition will establish EDPR NA’s presence in the downstream solar energy market as an owner-operator of one of the largest commercial and industrial distributed generation portfolios in the U.S. EDPR will acquire an 85% equity stake in C2’s solar portfolio that includes 89 MW of operating and near completion capacity across multiple sites and a near-term pipeline...

WALL, N.J. and LANHAM, Md., Jan. 19, 2021 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity and access management (IAM) solutions powered by biometrics, today announced a new partnership with NGEN LLC, a managed service provider based in Lanham, MD, who has been consistently recognized by CRN Magazine as among the fastest growing IT Service Providers in North America. The partnership has already generated a new customer for BIO-key’s PortalGuard® Identity-as-a-Service (IDaaS) platform through the Maryland Education Enterprise Consortium (MEEC) contract vehicle.NGEN’s higher education customer supports 14,000+ users and seeks to secure the online user experience across the institution by implementing advanced IAM practices, such as multi-factor authentication, which can...

Hyderabad, January 19, 2021: Tide, the UK’s leading business banking fintech has chosen India for its first overseas foray with a test launch slated for the first quarter of 2021, with a wider national roll-out later in 2021. Tide has already incorporated a local subsidiary for the launch with the India CEO & commercial team being based out of Gurgaon, and a second office in Hyderabad. Hyderabad is the site of Tide’s global development center with 100+ technology professionals already onboard. The teams in Hyderabad and Delhi NCR will grow rapidly to support the build of Tide India. The India business will be led by Gurjodhpal Singh, previously a senior executive at PayU, India’s leading PSP business. He will be supported by Tide CEO, Oliver Prill and CTO, Guy Duncan, who have both run international businesses with significant exposure...